BR112014032316A2 - proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta - Google Patents

proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta

Info

Publication number
BR112014032316A2
BR112014032316A2 BR112014032316A BR112014032316A BR112014032316A2 BR 112014032316 A2 BR112014032316 A2 BR 112014032316A2 BR 112014032316 A BR112014032316 A BR 112014032316A BR 112014032316 A BR112014032316 A BR 112014032316A BR 112014032316 A2 BR112014032316 A2 BR 112014032316A2
Authority
BR
Brazil
Prior art keywords
proteins
platelet
bind
growth factor
derived growth
Prior art date
Application number
BR112014032316A
Other languages
English (en)
Inventor
Baumann Michael
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of BR112014032316A2 publication Critical patent/BR112014032316A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Abstract

resumo patente de invenção: "proteínas de repetição de anquirina projetadas que se ligam a um fator de crescimento derivado de plaqueta". a presente invenção refere-se a novas proteínas de repetição de anquirina projetadas com especificidade de ligação para pdgf-bb que estão descritas, assim como ácidos nucleicos que codificam tais proteínas de ligação de pdgf, composições farmacêuticas que compreendem tais proteínas e o uso de tais proteínas no tratamento de doenças.
BR112014032316A 2012-06-28 2013-06-27 proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta BR112014032316A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12174020 2012-06-28
PCT/EP2013/063488 WO2014001442A1 (en) 2012-06-28 2013-06-27 Designed ankyrin repeat proteins binding to platelet-derived growth factor

Publications (1)

Publication Number Publication Date
BR112014032316A2 true BR112014032316A2 (pt) 2017-06-27

Family

ID=48699826

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032316A BR112014032316A2 (pt) 2012-06-28 2013-06-27 proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta

Country Status (16)

Country Link
US (2) US9163070B2 (pt)
EP (1) EP2867360B1 (pt)
JP (1) JP2015522576A (pt)
KR (1) KR20150023957A (pt)
CN (1) CN104508129A (pt)
AU (1) AU2013283296A1 (pt)
BR (1) BR112014032316A2 (pt)
CA (1) CA2877584A1 (pt)
HK (1) HK1209156A1 (pt)
IL (1) IL236428A0 (pt)
IN (1) IN2014MN02522A (pt)
MX (1) MX2014015825A (pt)
RU (1) RU2014150224A (pt)
SG (1) SG11201408196RA (pt)
WO (1) WO2014001442A1 (pt)
ZA (1) ZA201408872B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CN103459415B (zh) 2010-11-26 2021-04-09 分子组合公司 设计的与血清白蛋白结合的重复蛋白
HUE046134T2 (hu) 2012-05-07 2020-02-28 Allergan Inc Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
WO2020074469A1 (en) 2018-10-08 2020-04-16 Universität Zürich Her2-binding tetrameric polypeptides
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014191574A1 (en) 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
JP2017526053A (ja) 2014-07-07 2017-09-07 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． コンピュータ計算によるタンパク質設計方法
WO2016023898A2 (en) * 2014-08-11 2016-02-18 Medimmune Limited Intracellular antigen binding
JP6787888B2 (ja) 2014-11-10 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｉｌ−１ベータ抗体及び使用方法
CA2963606A1 (en) 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
KR20170080584A (ko) * 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
JP6946184B2 (ja) 2014-11-10 2021-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｐｄｇｆ−ｂ抗体及び使用法
AU2016240220B2 (en) 2015-04-02 2019-11-21 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
US10283384B2 (en) * 2015-04-27 2019-05-07 Taiwan Semiconductor Manufacturing Co., Ltd. Method for etching etch layer and wafer etching apparatus
NZ751689A (en) 2016-09-22 2021-07-30 Molecular Partners Ag Recombinant binding proteins and their use
US10037890B2 (en) * 2016-10-11 2018-07-31 Lam Research Corporation Method for selectively etching with reduced aspect ratio dependence
WO2018165046A1 (en) 2017-03-07 2018-09-13 Igc Bio, Inc. A computational pipeline for antibody modeling and design
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
CN111886338A (zh) 2018-03-22 2020-11-03 柏林夏瑞蒂医科大学 Crispr相关蛋白反应性t细胞免疫
US20210253723A1 (en) 2018-06-15 2021-08-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
EP3883919A1 (en) 2018-11-21 2021-09-29 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
EP3677911A3 (en) 2019-01-03 2020-07-29 Universität Basel Use of non-agonist ligands for suppression of metastasis
US20220088144A1 (en) 2019-01-11 2022-03-24 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
EP3953712A1 (en) 2019-04-10 2022-02-16 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
WO2020245746A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins
AU2020286600A1 (en) * 2019-06-04 2021-12-23 Molecular Partners Ag Recombinant FAP binding proteins and their use
WO2021044050A1 (en) 2019-09-05 2021-03-11 Genome Biologics Ug Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
CA3161326A1 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
WO2021204781A1 (en) 2020-04-06 2021-10-14 Universität Zürich Artc1 ligands for cancer treatment
IL297940A (en) * 2020-05-06 2023-01-01 Molecular Partners Ag New ankyrin repeat binding proteins and their uses
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
US20230303680A1 (en) 2020-08-18 2023-09-28 Universität Zürich A cd25-biased anti-il-2 antibody
WO2022130300A1 (en) 2020-12-16 2022-06-23 Molecular Partners Ag Novel slow-release prodrugs
EP4291901A1 (en) 2021-02-11 2023-12-20 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
CA3211368A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
AU2022231913A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd33 engagers
KR20230155464A (ko) 2021-03-09 2023-11-10 몰리큘라 파트너스 아게 신규한 DARPin-기반 다중특이성 T-세포 인게이저
JP2024509890A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト プロテアーゼ切断可能なプロドラッグ
IL310615A (en) 2021-08-05 2024-04-01 Immunos Therapeutics Ag Pharmaceutical compositions comprising HLA fusion proteins
WO2023012350A1 (en) 2021-08-05 2023-02-09 Immunos Therapeutics Ag Combination medicaments comprising hla fusion proteins
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (en) 2021-10-08 2023-04-12 ETH Zurich Device and method for manipulation of extracellular vesicles
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
EP4260907A1 (en) 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
EP0975748B1 (en) 1997-04-23 2006-03-29 Universität Zürich Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
ATE354675T1 (de) 1998-12-02 2007-03-15 Adnexus Therapeutics Inc Dna-protein fusionen sowie anwendungen derselben
US7417130B2 (en) * 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
CA2460587A1 (en) * 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anti-pdgf antibodies and methods for producing engineered antibodies
AU2004268614C1 (en) * 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
NZ554429A (en) * 2004-11-12 2010-08-27 Bayer Schering Pharma Ag Recombinant newcastle disease virus comprising a transgene encoding a antibody or antibody like fragment or derivative thereof for use in cancer treatments
WO2006129828A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Target substance capturing molecule
CA2614512C (en) 2005-07-08 2014-01-07 University Of Zuerich Phage display using cotranslational translocation of fusion polypeptides
AU2007223888A1 (en) 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
KR101631323B1 (ko) 2007-06-21 2016-06-17 엑스엘-프로테인 게엠베하 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질
CA2706419A1 (en) 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs binding il-13
US20100317599A1 (en) * 2008-02-13 2010-12-16 Alrik Pieter Los Process for the production of a peptide
US20110262964A1 (en) * 2008-03-19 2011-10-27 Hugues Bedouelle Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
CN107011425B (zh) * 2008-11-03 2021-01-01 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
AR081361A1 (es) * 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CN103459415B (zh) 2010-11-26 2021-04-09 分子组合公司 设计的与血清白蛋白结合的重复蛋白
CN104105704A (zh) * 2011-04-29 2014-10-15 詹森生物科技公司 Il4/il13结合重复蛋白及用途

Also Published As

Publication number Publication date
US9163070B2 (en) 2015-10-20
US20150368302A1 (en) 2015-12-24
EP2867360B1 (en) 2019-05-08
EP2867360A1 (en) 2015-05-06
IL236428A0 (en) 2015-02-26
KR20150023957A (ko) 2015-03-05
IN2014MN02522A (pt) 2015-07-17
CA2877584A1 (en) 2014-01-03
JP2015522576A (ja) 2015-08-06
RU2014150224A (ru) 2016-08-20
US20140005125A1 (en) 2014-01-02
MX2014015825A (es) 2015-08-10
SG11201408196RA (en) 2015-03-30
ZA201408872B (en) 2016-05-25
AU2013283296A1 (en) 2015-02-05
CN104508129A (zh) 2015-04-08
HK1209156A1 (en) 2016-03-24
WO2014001442A1 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
ECSP17061751A (es) Nuevas proteínas específicas para pioverdina y pioquelina
PH12017501583A1 (en) Novel proteins specific for cd137
CY1118014T1 (el) Aνti-il-23 αντισωματα
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
MX2012011771A (es) Aptameros para beta-ngf y su uso en el tratamiento de enfermedades y trastornos mediados por beta-ngf.
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
EA201400871A1 (ru) Способ доставки нуклеиновых кислот с разделением, их композиции и использование
BR112013020259A2 (pt) tratamento de osteoartrite e dores
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
EA200870594A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
MX347535B (es) Proteinas de union modificadas que inhiben la interaccion de receptor vegf-a.
MX2021010668A (es) Proteinas de fusion de citoquinas.
BR112012007294A2 (pt) moléculas de ligação a dll4
PH12015501687A1 (en) Novel binding proteins from pcsk9
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
EA201401117A1 (ru) Композиции, содержащие пробиотики и комплекс пчелиной пыльцы/глины, способ их приготовления и их применение в питании и терапии
MX2015016120A (es) Moleculas de union que se adhieren al factor de complemento c2 humano y usos de los mismos.
ECSP18008488A (es) Moléculas de fusión
BR112013013960A8 (pt) Composi%c3%87%c3%95es de vacinas de mal%c3%81ria, polipept%c3%8ddeos, fragmentos do mesmo, mol%c3%89culas de %c3%81cido nucleico, e usos destes
EA201200182A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
WO2011137441A3 (en) Sparc binding aptamers and uses thereof
CY1115984T1 (el) Νεες amino αζαετεροκυκλικες καρβοξαμιδες

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]